ArticleAmerican journal of preventive medicine2026
Association of Continuous Medicaid Eligibility With Postpartum Coverage and Opioid Use Disorder Treatment.
Article in American journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionOver three quarters of pregnant people with opioid use disorder are enrolled in Medicaid at delivery, but pregnancy-related Medicaid eligibility has historically ended 60 days postpartum, leading to periods without insurance and decreased access to health care during the first year postpartum. The Families First Coronavirus Response Act, passed in March 2020, prevented states from disenrolling Medicaid enrollees, including postpartum enrollees, during the COVID-19 Public Health Emergency.
methodsA difference-in-difference model was used to compare the continuity of coverage among postpartum persons with opioid use disorder in Medicaid versus commercial insurance before and after the Families First Coronavirus Response Act . A segmented regression model was used to assess medication for opioid use disorder retention (at 6 and 12 months) among those with Medicaid at delivery before (2016-2019) versus after Families First Coronavirus Response Act (2020-2022).
resultsAmong deliveries from 2016 to 2022, 1,435 (10.2%) were enrolled in commercial insurance, and 12,567 (89.8%) were in Medicaid. In the pre-Families First Coronavirus Response Act period, 60.0% of commercially insured and 63.5% of Medicaid-insured deliveries remained enrolled through 12-months postpartum. In adjusted analyses, the Families First Coronavirus Response Act was associated with a 23.2 percentage-point (95% CI=17.6%, 28.8%) increase in 12-month continuous Medicaid coverage compared with that among commercially insured individuals. Among Medicaid enrollees, medication for opioid use disorder retention increased by 14.4 (95% CI=8.2, 20.6) and 16.3 (95% CI=10.1, 22.5) percentage points (level change) in 6- and 12-month medication for opioid use disorder retention, respectively, after the Families First Coronavirus Response Act.
conclusionsIn this observational study, the Families First Coronavirus Response Act was associated with increased health insurance stability and improved medication for opioid use disorder retention among postpartum Medicaid beneficiaries with opioid use disorder. These findings suggest that postpartum Medicaid extensions, implemented in 49 states and Washington, DC, could help increase insurance coverage stability and medication for opioid use disorder use for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.